NextSource Biotechnology Gains FDA Approval For Use Of Tradename Gleostine™ (Lomustine), An Anti-Cancer Chemotherapy Agent. The Approved Gleostine™ Brand Name Has Replaced The Discontinued Former Drug Name CeeNu®
MIAMI, Aug. 7, 2014 /PRNewswire/ -- NextSource Biotechnology (NSB) is a leading specialty pharmaceutical manufacturer with a focus on identifying and developing the most viable pipeline of "matured" and "innovative drugs" in today's global healthcare market. The product name change from Lomustine (CCNU) to GleostineTM represents the company's strategic initiative to re-launch and re-brand its product pipeline of matured and innovative drugs.
Read more »
NextSource Biotechnology Announces FDA Short Supply release of the formally known Bristol Myers Squibb (CeeNu®) Brand Oncology product now currently marketed under the NextSource Biotechnology Lomustine (CCNU) label Exclusively in the United States.
MIAMI, Jan. 24, 2014 -- NextSource BioTechnology, LLC, (NSB), an emerging Specialty Pharmaceutical Manufacturing and Marketing Company
focused on Consolidating, Re-Branding and Launching "Matured & Orphan Drugs," has announced its most recent product Lomustine (CCNU)... Read more »
NextSource Biotechnology Launches New Strategic Approach to Mitigate Slow-Downs in Manufacturing of Matured Medications in High Demand. NextSource Biotechnology Re-Introduces Critical Oncology Medication avoiding major losses in the Healthcare Sector.
MIAMI, Sept. 23, 2013 -- NextSource Biotechnology, LLC., (NSB), a leading Specialty Pharmaceutical Manufacturing and Marketing
company with a strategic objective of Consolidating, Re-Branding and launching a "Matured & Orphan Drugs" product portfolio in the U.S. and
International Healthcare Markets. By utilizing a worldwide distribution network... Read more »